Summary:
The purpose of this study is to understand whether the drug, pimavanserin, improves symptoms of hallucinations and/or delusions experienced in people with dementia.
Qualified Participants Must:
Have been diagnosed with dementia, dementia with Lewy bodies (DLB), Parkinson's disease dementia (PPD), Alzheimer's disease, frontotemporal degeneration, or vascular dementia
Have experienced hallucinations (seeing, hearing, or otherwise sensing things that aren't there) and/or delusions (false or mitaken beliefs) for at least 2 months
Be between 50 and 90 years of age
Have a study partner who is able to attend study visits
Qualified Participants May Receive:
All participants will be given pimavanserin in the first part of the study. If their hallucinations or delusions improve, participants may qualify for the second part of the study; Compensation is available for time and travel